Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mapatumumab plus sorafenib vs placebo plus sorafenib in advanced hepatocellular carcinoma
2010-020798-17Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Mapatumumab + sorafenib with Placebo + sorafenib (2 arms). Primary endpoint: Time to progression. Started Feb 2011; status: completed.
02
Drugs
mapatumumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2010-020798-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020798-17.